Agios Highlights RISE UP Phase 3 Results at EHA 2026
CAMBRIDGE, Mass., June 13, 2026 Agios Pharmaceuticals, Inc. announced detailed results from the 52-week double-blind portion of the global...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., June 13, 2026 Agios Pharmaceuticals, Inc. announced detailed results from the 52-week double-blind portion of the global...
